127 related articles for article (PubMed ID: 7815310)
21. Anti-r-hirudin antibodies reveal clinical relevance through direct functional inactivation of r-hirudin or prolongation of r-hirudin's plasma halflife.
Huhle G; Liebe V; Hudek R; Heene DL
Thromb Haemost; 2001 May; 85(5):936-8. PubMed ID: 11372692
[No Abstract] [Full Text] [Related]
22. Recombinant hirudin as a periprocedural antithrombotic in coronary angioplasty for unstable angina pectoris.
Hafner G; Rupprecht HJ; Luz M; Terres W; Schindel F; Friesen HJ; Heinrichs H; Jessel A; Meyer J; Prellwitz W
Eur Heart J; 1996 Aug; 17(8):1207-15. PubMed ID: 8869862
[TBL] [Abstract][Full Text] [Related]
23. Pharmacodynamics and pharmacokinetics of polyethylene glycol-hirudin in patients with chronic renal failure.
Pöschel KA; Bucha E; Esslinger HU; Nörtersheuser P; Jansa U; Schindler S; Nowak G; Stein G
Kidney Int; 2000 Dec; 58(6):2478-84. PubMed ID: 11115081
[TBL] [Abstract][Full Text] [Related]
24. Influence of recombinant hirudin on tissue-factor-induced activation of coagulation in rabbits.
Kouz J; Czech J; Nicolay U; Dickneite G
Haemostasis; 1996; 26(4):179-86. PubMed ID: 8872128
[TBL] [Abstract][Full Text] [Related]
25. Pharmacology of r-hirudin in renal impairment.
Nowak G; Bucha E; Gööck T; Thieler H; Markwardt F
Thromb Res; 1992 Jun; 66(6):707-15. PubMed ID: 1519229
[TBL] [Abstract][Full Text] [Related]
26. [Subcutaneous recombinant hirudin in the treatment of deep venous thrombosis. A pharmacokinetic study].
Schiele F; Vuillemenot A; Mouhat T; Kramarz P; Kieffer Y; Camez A; Bassand JP
Arch Mal Coeur Vaiss; 1995 Mar; 88(3):329-35. PubMed ID: 7487286
[TBL] [Abstract][Full Text] [Related]
27. Clinical use of hirudin.
Vogel G; Markwardt F
Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):113-8. PubMed ID: 2459004
[TBL] [Abstract][Full Text] [Related]
28. A recombinant hirudin (IK-HIR02) in healthy volunteers. II. Effects on platelet adhesion and platelet-induced thrombin generation time.
Schenk JF; Glusa E; Radziwon P; Butti A; Markwardt F; Breddin HK
Haemostasis; 1996; 26(4):187-94. PubMed ID: 8872129
[TBL] [Abstract][Full Text] [Related]
29. Anti-hirudin antibodies alter pharmacokinetics and pharmacodynamics of recombinant hirudin.
Fischer KG; Liebe V; Hudek R; Piazolo L; Haase KK; Borggrefe M; Huhle G
Thromb Haemost; 2003 Jun; 89(6):973-82. PubMed ID: 12783109
[TBL] [Abstract][Full Text] [Related]
30. Pharmacological survey of recombinant hirudin.
Markwardt F; Fink G; Kaiser B; Klöcking HP; Nowak G; Richter M; Stürzebecher J
Pharmazie; 1988 Mar; 43(3):202-7. PubMed ID: 3380865
[TBL] [Abstract][Full Text] [Related]
31. Direct thrombin inhibition with Rec-hirudin CGP 39393 as prophylaxis of thromboembolic complications after total hip replacement.
Eriksson BI; Kälebo P; Ekman S; Lindbratt S; Kerry R; Close P
Thromb Haemost; 1994 Aug; 72(2):227-31. PubMed ID: 7831657
[TBL] [Abstract][Full Text] [Related]
32. Anticoagulant efficacy of PEG-Hirudin in patients on maintenance hemodialysis.
Pöschel KA; Bucha E; Esslinger HU; Ulbricht K; Nörtersheuser P; Stein G; Nowak G
Kidney Int; 2004 Feb; 65(2):666-74. PubMed ID: 14717940
[TBL] [Abstract][Full Text] [Related]
33. Immunoassays in monitoring biotechnological drugs.
Gygax D; Botta L; Ehrat M; Graf P; Lefèvre G; Oroszlan P; Pfister C
Ther Drug Monit; 1996 Aug; 18(4):405-9. PubMed ID: 8857560
[TBL] [Abstract][Full Text] [Related]
34. The effect of a long-acting recombinant hirudin (PEG-hirudin) on experimental disseminated intravascular coagulation (DIC) in rabbits.
Zawilska K; Zozulinska M; Turowiecka Z; Blahut M; Drobnik L; Vinazzer H
Thromb Res; 1993 Feb; 69(3):315-20. PubMed ID: 8475480
[TBL] [Abstract][Full Text] [Related]
35. [The pharmacokinetics and pharmacodynamics of recombinant hirudin-2 nasal spray].
Zhang YJ; Zhang Q; Hou JL; Wang XL; Chen MX
Yao Xue Xue Bao; 2006 Mar; 41(3):268-71. PubMed ID: 16759001
[TBL] [Abstract][Full Text] [Related]
36. Potential use of recombinant hirudin as an anticoagulant in a cardiopulmonary bypass model.
Walenga JM; Bakhos M; Messmore HL; Fareed J; Pifarre R
Ann Thorac Surg; 1991 Feb; 51(2):271-7. PubMed ID: 1989543
[TBL] [Abstract][Full Text] [Related]
37. Pharmacodynamics and pharmacokinetics of recombinant hirudin via four non-parenteral routes.
Liu Y; Lu WL; Zhang X; Wang XQ; Zhang H; Zhang Q
Peptides; 2005 Mar; 26(3):423-30. PubMed ID: 15652649
[TBL] [Abstract][Full Text] [Related]
38. The pharmacokinetics of etanercept in healthy volunteers.
Korth-Bradley JM; Rubin AS; Hanna RK; Simcoe DK; Lebsack ME
Ann Pharmacother; 2000 Feb; 34(2):161-4. PubMed ID: 10676822
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics and anticoagulant effect of hirudin in man.
Markwardt F; Nowak G; Stürzebecher J; Griessbach U; Walsmann P; Vogel G
Thromb Haemost; 1984 Oct; 52(2):160-3. PubMed ID: 6523433
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics of hirudin.
Nowak G
Semin Thromb Hemost; 1991 Apr; 17(2):145-9. PubMed ID: 1771412
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
